RxDoctor Payments Data

Iman Parhami

Psychiatry · Woodland Hills, CANPI 1134482367

Payments from drug & device makers

$585,062in general payments, 2019–2025

Across 90 payments — averaging $6500.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370K
  • Boehringer Ingelheim$141K
  • Janssen Research & Development, LLC$46K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22K
  • Boehringer Ingelheim International GmbH$6K
  • Janssen Scientific Affairs, LLC$200
  • plus $257 from 5 others
$1,307in research payments, 2019–2025

Across 10 payments — averaging $130.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Consulting fees$20044%
  • Food & beverage$25756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$585,062 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$184,571
Medicare patients
69
Services billed
1,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl52$160,105
RexultiBrexpiprazole15$31,422
Lurasidone Hcl22$8,853
Clozapine20$1,834
Duloxetine Hcl53$1,212
Zolpidem Tartrate18$889
Mirtazapine40$761
Quetiapine Fumarate64$542
Clonazepam50$458
Divalproex Sodium27$451
Bupropion XlBupropion Hcl30$333
Venlafaxine Hcl ErVenlafaxine Hcl12$332
Olanzapine35$313
Sertraline Hcl83$290
Alprazolam39$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$55$160,10552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Woodland Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →